---
title: "Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 | ACET Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274307074.md"
description: "Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company, announced that CEO Chen Schor will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026, at 2:00 p.m. ET in New York. The presentation will be accessible via a live audio webcast on the company's website, with an archived replay available for 30 days."
datetime: "2026-01-30T04:00:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274307074.md)
  - [en](https://longbridge.com/en/news/274307074.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274307074.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274307074.md) | [繁體中文](https://longbridge.com/zh-HK/news/274307074.md)


# Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 | ACET Stock News

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 being held from February 11-12, 2026 in New York.

Details of the event are as follows:  
Date: Thursday, February 12, 2026  
Time: 2:00p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

**About Adicet Bio, Inc.**

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260130979631/en/

**Adicet Bio., Inc.**  
**Investor and Media Contacts**

Anne Bowdidge  
abowdidge@adicetbio.com

Penelope Belnap  
Precision AQ  
penelope.belnap@precisionaq.com

Source: Adicet Bio, Inc.

### Related Stocks

- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [Adicet Bio, Inc. (ACET.US)](https://longbridge.com/en/quote/ACET.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)

## Related News & Research

- [Rallybio to acquire Candid Therapeutics](https://longbridge.com/en/news/277617458.md)
- [Caribou Biosciences Q4 licensing revenue rises, net loss narrows](https://longbridge.com/en/news/277986902.md)
- [Bioventus beats Q4 revenue estimates on strong demand for pain treatments and surgical solutions](https://longbridge.com/en/news/277932436.md)
- [FDA official calls UniQure's Huntington's disease treatment a failure](https://longbridge.com/en/news/278017726.md)
- [Anavex Life Sciences Touts Oral Alzheimer’s Drug Blarcamesine Data, Cash Runway at Healthcare Conference](https://longbridge.com/en/news/277943726.md)